Yazici Y, Erkan D, Lockshin M D
Division of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, USA.
Clin Exp Rheumatol. 2000 Nov-Dec;18(6):732-4.
To survey the effectiveness of etanercept in the treatment of severe, resistant psoriatic arthritis.
Ten patients coming from the clinical practice of 5 different rheumatologists and already using etanercept (25 mg subcutaneously twice weekly) were formally assessed at 3 and 12 months after etanercept use.
All patients had improvement in their arthritis. Five of the 10 patients had no arthritis, 4 required only etanercept for disease control at 3 months. At 12 months, 8 of 10 patients were still on etanercept with continued good response. One patient had to discontinue etanercept due to osteomyelitis, and one due to increased disease activity. Of 4 patients with active skin disease, 3 had complete clearing. There were no side effects related to etanercept in this small, heterogeneously collected group of patients.
This preliminary and rather favorable experience with etanercept suggests that properly controlled trials of this agent in psoriatic arthritis are needed.
调查依那西普治疗重度、难治性银屑病关节炎的有效性。
来自5位不同风湿病专家临床实践且已使用依那西普（每周两次皮下注射25毫克）的10名患者，在使用依那西普后3个月和12个月时进行了正式评估。
所有患者的关节炎均有改善。10名患者中有5名无关节炎，4名在3个月时仅需依那西普控制病情。在12个月时，10名患者中有8名仍在使用依那西普，且持续有良好反应。1名患者因骨髓炎不得不停用依那西普，1名因疾病活动增加而停药。4名有活动性皮肤病的患者中，3名完全清除。在这个收集方式各异的小患者组中，未出现与依那西普相关的副作用。
依那西普的这一初步且颇为良好的经验表明，需要对该药物在银屑病关节炎中进行适当对照试验。
